Research Reference
Insulin
Essential peptide hormone for glucose regulation
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Insulin is an essential peptide hormone that regulates blood glucose and has been used as a medicine since 1923. Multiple FDA-approved formulations exist for diabetes management.
Dosing Reference
Reconstitution
Add 10 mL bacteriostatic water to the 100 mg vial. Resulting concentration: 10 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 5 mg | 50 units | 0.5 mL | SubQ, per carb intake / glucoseIndividualized (U-100) |
| 10 mg | 100 units | 1 mL | SubQ, per carb intake / glucoseIndividualized (U-100) |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Insulin is FDA-approved for diabetes mellitus and is supplied as a solution/suspension in vials (U-100 = 100 units/mL) or pre-filled pens. It is not user-reconstituted from lyophilized powder except for specific concentrated formulations per manufacturer instructions. Compounded forms are not FDA-approved.
Standard insulin is U-100 (100 units/mL); a 10-unit dose draws to 10 units (0.1 mL) on a U-100 syringe. Concentrated U-500 (500 units/mL) is used for severe insulin resistance. Store per manufacturer directions; compounded forms are not FDA-approved.
Cycling Protocol
FDA-approved insulin dosing is fully individualized to carbohydrate intake, blood glucose, activity, and insulin sensitivity — there is no fixed cycle. Basal-bolus regimens use a long-acting basal once daily plus rapid-acting boluses before meals, titrated to glucose targets.
Routes of Administration
Subcutaneous injection (primary FDA-approved route): Into the abdomen, thigh, or upper arm; rotate sites. Rapid-acting (before meals), short-acting, intermediate, and long-acting (basal) formulations.
Inhaled (FDA-approved): Afrezza inhaled insulin before meals.
Compounded forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Basal-bolus | Long-acting basal + rapid-acting bolus | Standard MDI protocol (FDA) | | Insulin + GLP-1 | Insulin + GLP-1 agonist | Studied T2D combination (FDA, under supervision) | | Insulin + pramlintide | Insulin + pramlintide | FDA-approved adjunct (reduce prandial insulin) |
Insulin combinations are managed under specialist endocrinology supervision. Compounded forms are not FDA-approved.
Side Effects & Safety
- Hypoglycemia — most significant risk; can be severe/life-threatening
- Weight gain — common
- Injection-site reactions / lipohypertrophy — common; rotate sites
- Lipodystrophy — risk with repeated same-site injection
- Allergic reactions — rare
- Hypokalemia — risk
Insulin is FDA-approved for diabetes mellitus. Dosing is highly individualized and managed under endocrinology supervision. Compounded forms are not FDA-approved.
Research Basis
Insulin is the naturally occurring peptide hormone produced by pancreatic beta cells, FDA-approved for diabetes mellitus (multiple formulations).
Mechanism: Binds the insulin receptor to promote cellular glucose uptake, glycogen synthesis, lipogenesis, and protein synthesis; suppresses hepatic glucose production.
Clinical evidence: FDA-approved for type 1 and type 2 diabetes mellitus (1922 onward). Multiple formulations (rapid-, short-, intermediate-, long-acting, inhaled) with extensive clinical experience.
FDA-approved for diabetes mellitus. Dosing is highly individualized. Compounded forms are not FDA-approved.